Skip to main content

Something isn't right in the world of pharmaceuticals. Alarm bells are ringng.


Something is not right in the world of pharmaceuticals. But it isn't reflected in the number of new drugs coming to market.

The widely held belief that the UK supply of innovative new medicines has conspicuously dwindled in recent decades, is not borne out by the evidence, or at least this is what is suggested by research published in the online journal BMJ Open.

The prevailing view is that pharmaceutical industry innovation has been in decline, with fewer new drugs launched in recent decades than before—despite more cash being pumped into research and development—prompting a good deal of hand-wringing, say the authors.

They tested whether this view was justified, by looking at all new medicines added every year to the prescribing and dispensing drugs bible, the British National Formulary, or BNF for short, over 30 years. The BNF is updated every six months.

In terms of the drugs industry, the UK punches above its weight. After the US, the UK is the second largest source of new drug development, generating more than 10% of all new medicines around the globe.

All new synthetic chemical entities and new biological drugs, such as vaccines, blood products, and gene therapies were included, based on their first appearance in the BNF between 1982 and 2011.

New products covered modifications of existing drugs as well as radical breakthrough treatments. Different doses and formulations containing the same active ingredients were only counted once, and generic versions of brand drugs were excluded.

The researchers found no significant linear trend pointing to a decline in the number of new drugs introduced into the UK over that period, which averaged just under 24 a year.

But the authors did find a pattern of peaks and troughs, with dips invariably followed by a surge in new arrivals. New drugs, in seems, come in waves.

After a dip in the mid-1980s, with around a dozen new drugs coming on to the market between 1985 and 1987, new arrivals increased every year, peaking at 34 in 1997.

This peak was again followed by a dip, with around 20 new drugs a year between 2003 and 2006, followed by a further peak in 2010.

And extending the timeline back to the 1970s indicated an overall slight but significant increase of 0.16 new drugs every year between 1971 and 2011, “contradicting the widely held view that the number of new medicines being launched is declining,” say the authors.

They conclude that the perceived “innovation dip” is a product of the time periods studied in the past. A product of the cyclical nature of new drugs entering the market.

“Although there was indeed a dip in new drug introductions during the decade from 1997 to 2006, this was largely an artefact of a peak in 1997, which was itself preceded by an unusually low number of launches in 1985-87,” they write. “Additionally, the peak number of new drugs added to the BNF in 1997 was matched in 2010.”

The authors point out that their study does not distinguish between varying degrees of innovation, and launches are not the only indicator of pharmaceutical industry health. But theirs is the most up to date UK study of new launch trends, they say.

There are however, reasons to be concerned. As the authors point out, the costs of drug development have soared. and the time taken to bring a new drug to market has risen from 3 years in 1960 to 12 in 2000.

My own view is that the authors of the study published today may well be asking the wrong question; or at least using the wrong measure. It isn't the number of 'new' drugs that count; it is really how innovative they are and whether they really make a difference.

Alarm Bells

Alarm bells rang when it was announced recently that the world's leading pharmaceutical companies are downgrading the search for new treatments for Alzheimer's disease after the failure of a series of high-profile drugs trials.

Nor has there been the expected windfall following the sequencing of the human genome. Many leading scientists are disappointed that there have been few gene-centred drugs coming through from this project.

Tragically the genome project has sucked funding away from more traditional areas of research with little reward. A decade ago drug companies invested billions of dollars in genomic research and development. The shares of small genomics based companies went through the roof in a 'genomic bubble'.

In 2000 the then head of the drug company Novartis was reported to have observed “Data, data everywhere, and not a drug, I think.”

Genomics may be a misdirected quest for new drugs. There are few diseases or condition for which there is a specific gene. This is not surprising; genotype doesn't translate into phenotype.

Misdirected funding

Funding has been directed at 'translational' research in the absurd hope that this could somehow leap beyond the usual steps of scientific endeavour and discovery. It can't and it won't. But another problem of translational research is that it draws funding away from solid basic biomedical science from which new ideas will eventually come. 

Some of the really good innovative drugs have been founded on basic research. Genomics is more like a fishing expedition rather than good science. Major breakthroughs in treatment often come serendipitously rather than from targeting a problem and throwing money at it; but luck usually rides on good science.

This was certainly so for the developments of treatments for Asthma. It involved good basic science, good pharmacology and a bit of luck. It came in stages over time; first with the finding that adrenal extract could relieve symptoms, then the discovery of adrenaline and the categorisation of different adrenaline receptors which enabled drugs to be targeted at the right ones. It also involved understanding of how some drugs could act over time, and that more than one kind of drug was needed; one to relieve symptoms acting on the adrenaline receptors in the airway, and another, corticosteroid, to ease the inflammation.

The pharmaceutical industry needs to take stock and rethink its drug development strategy. Putting their eggs in the genomics basket will produce fewer answers then originally anticipated. Government and funding agencies need also to consider how to rejuvenate basic biomedical science and systems biology.

It is scandalous that drug companies should be giving up on diseases such as Altzheimer's. We should stop looking for magic bullets. Good science takes time and funding. Pharmaceutical companies looking for a quick buck have forgotten those basic ingredients.

Comments

Popular posts from this blog

Prioritising people in nursing care.

There has been in recent years concern that care in the NHS has not been sufficiently 'patient centred', or responsive to the needs of the patient on a case basis. It has been felt in care that it as been the patient who has had to adapt to the regime of care, rather than the other way around. Putting patients at the centre of care means being responsive to their needs and supporting them through the process of health care delivery.  Patients should not become identikit sausages in a production line. The nurses body, the Nursing and Midwifery Council has responded to this challenge with a revised code of practice reflection get changes in health and social care since the previous code was published in 2008. The Code describes the professional standards of practice and behaviour for nurses and midwives. Four themes describe what nurses and midwives are expected to do: prioritise people practise effectively preserve safety, and promote professionalism and trust. The

Half measures on heat pumps

Through the "Heat and Buildings Strategy", the UK government has set out its plan to incentivise people to install low-carbon heating systems in what it calls a simple, fair, and cheap way as they come to replace their old boilers over the coming decade.  New grants of £5,000 will be available from April next year to encourage homeowners to install more efficient, low carbon heating systems – like heat pumps that do not emit carbon when used – through a new £450 million 3-year Boiler Upgrade Scheme. However, it has been widely criticised as inadequate and a strategy without a strategy.  Essentially, it will benefit those who can afford more readily to replace their boiler.   Undoubtedly, the grants will be welcome to those who plan to replace their boilers in the next three years, and it might encourage others to do so, but for too many households, it leaves them between a rock and a hard place.  There are no plans to phase out gas boilers in existing homes.  Yet, that is wha

No real commitment on climate

Actions, they say, speak louder than words.  So, when we look at the UK government's actions, we can only conclude they don't mean what they say about the environment and climate change.  Despite their claims to be leading the charge on reducing emissions, the UK government is still looking to approve new oil fields.  The Prime Minister, Boris Johnson,  has announced his support for developing the Cambo oil field and 16 other climate-destroying oil projects. Cambo is an oil field in the North Sea, west of Shetland. A company called Siccar Point has applied for a permit to drill at least 170 million barrels of oil there. If it's allowed to go ahead, it will result in the emissions equivalent of 18 coal plants running for a year.  What? Yes, 18 coal plants a year!  Today, as I write, Greenpeace is demonstrating in Downing Street against this project.  I suppose it will get the usual government dismissal and complaints about inconveniencing others.  Well, we know it won't